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Abstract
Background: Although human immunodeficiency virus (HIV)–related morbidity and mortality rates in patients treated with
a combination of high active antiretroviral therapy (HAART) have declined, significant metabolic/vascular adverse effects
associated with the long term use of HIV protease inhibitors (PIs) have emerged as a significant side effect. Here we illustrate
that targeting the bile acid sensor farnesoid X receptor (FXR) protects against dyslipidemia and vascular injury induced HIV-
PIs in rodents.
Methodology/Principal Findings: AdministrationoftheHIVPIritonavirtowildtypemiceincreasedplasmatriacylglycerolsand
cholesterol levels and thiseffectwas exacerbated bydosingritonavirtomiceharbouring a disrupted FXR.Dyslipidemia induced
byritonavirassociated witha shiftin the liver expressionofsignature genes,Sterol RegulatoryElement-Binding Protein(SREBP)-
1 and fatty acid synthase. Treating wild type mice with the FXR agonist (chenodeoxycholic acid, CDCA) protected against
development of dyslipidemia induced by ritonavir. Administration of ritonavir to ApoE
2/2 mice, a strain that develop
spontaneously atherosclerosis, increased the extent of aortic plaques without worsening the dyslipidemia. Treating these mice
with CDCA reduced the extent of aortic plaques by 70% without changing plasma lipoproteins or the liver expression of
signature genes. A beneficial effect on aortic plaques was also obtained by treating ApoE
2/2 mice with gemfibrozil, a PPARa
agonist. FXR activation counter-regulated induction of expression/activity of CD36 caused by HIV-PIs in circulating monocytes
and aortic plaques. In macrophages cell lines, CDCA attenuated CD36 induction and uptake of acetylated LDL caused by
ritonavir. Natural and synthetic FXR ligands reduced the nuclear translocation of SREBP1c caused by ritonavir.
Conclusions/Significance: Activation of the bile acid sensor FXR protects against dyslipidemia and atherosclerotic caused
by ritonavir, a widely used HIV PI. From a mechanistic stand point it appears that besides reducing the liver expression of
genes involved in fatty acid synthesis, FXR activation counter-regulates the expression/activity of CD36 on monocytes. FXR
ligands might hold promise in the treatment dyslipidemia induced by ritonavir.
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Introduction
Protease inhibitors (PI) as a part of highly active anti-retroviral
therapy (HAART) have been used successfully in the treatment of
human immunodeficiency virus (HIV) infection. Incorporation of
HIV protease inhibitors in the HAART causes profound and
sustained suppression of viral replication, significantly reduces the
morbidity and mortality, and prolongs the lifespan of patients with
HIV infection [1,2]. HAART has changed the clinical profile of
HIV infection from a sub-acute lethal disease to a chronic
ambulatory disease [2,3]. Despite its efficacy in controlling the
disease progression, the use of PI therapy associates with an
increased risk of development of premature atherosclerosis. This is
particularly true in younger patients (men under the age of 34 and
women under the age of 44) [1–4]. Although the mechanism
underlying HIV PI-induced atherosclerosis remains to be fully
identified, an increasing body of evidence suggests that ttreatment
of HIV-infected patients with HIV PIs causes a dyslipidemia
which contributes to the development of cardiovascular diseases
[4]. A significant increase in plasma triacylglycerols and total
cholesterol concentrations, often associated with abnormal body
fat distribution and peripheral insulin resistance (hyperinsulinemia,
hyperglycemia and diabetes mellitus), has been detected in HIV
PIs-treated patients [5–8]. There is evidence that such pro-
atherogenetic lipid profile induced by PIs in linked to the effect
these agents exert on the Sterol Regulatory Element-Binding
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transcription factors that sense liver cholesterol concentrations.
In hepatocytes and adipocytes, activation or extended life span of
SREBP proteins, resulting from suppression of activated SREBP
degradation, causes the nuclear accumulation of activated
SREBP-1 and 2 leading to increased lipogenesis by induction of
lipogenetic genes such as the fatty acid synthase (FAS) [9,10].
In addition to these effects, PIs act directly on macrophages,
another important player in the formation of atherosclerotic
plaques. In vitro studies have shown that exposure of macrophages
to HIV PIs increases the accumulation of free cholesterol, activates
the unfolded protein response (UPR), induces apoptosis, and
promotes transition toward a foam cell phenotype [11]. Macro-
phage’s recruitment into the vascular wall is one of the earliest
events in atherogenesis. This event is mediated by the up-
regulation of the scavenger receptor-dependent uptake of
lipoprotein sterols by macrophages in the sub-endothelial space,
which contributes to the formation of lipid-laden macrophages
[13]. The class B scavenger receptor, CD36, mediates the uptake
of oxidized (ox) LDL particles by macrophages [13] and is a well
identified target of HIV PIs, although the mechanisms that
regulate the induction of its expression/activity in response HIV
PIs remain elusive [12].
FXR (NR1H4) is an adopted member of the nuclear receptor
super-family of ligand-activated regulatory factor highly expressed
in entero-hepatic tissues. In the liver, FXR serves as a bile acid
sensor and regulates bile acid synthesis and excretion [14]. In target
tissues, primary bile acids, cheno-deoxycholic acid (CDCA) and
cholic acid (CA), bind and activate the receptor at micromolar
concentrations leading to feedback repression of bile acid
biosynthesis, an effect that is primarily achieved by repressing the
expression/activity of the cholesterol 7a-hydroxylase (CYP7A1), a
gene encodingfor a protein that regulates the first, and ratelimiting,
enzymatic step of cholesterol breakdown. Other than bile acid
synthesis, FXR intervenes in a variety of physiological processes. In
mice, FXR deficiency results in a pro-atherogenic serum lipoprotein
profile [15], while FXR agonism reduces triacylglycerols by
repressing the expression and activity of SREBP1c in the liver.
The phenotypic readouts of these effects is a reduction of the pro-
atherogenic lipid profile and an attenuation of the tendency toward
development of atherosclerotic plaques in ApoE
2/2 and LDLr
2/2
mice [16–17], two genetic models of dyslipidemia-driven athero-
sclerosis, as well as in rodents strains characterised by insulin
resistance and liver steatosis [16–20]. Further on FXR is expressed
by cells of innate immunity and both natural and synthetic FXR
ligands counter-regulate macrophage activation induced by Toll-
like receptor (TLR)-4 ligands [17]. This regulatory effects of FXR
on macrophage effector’s function is inhibitory in nature and
translatesinvivoinanattenuated formationofaorticplaquesaswell
as reduced expression of CD36 on circulating monocytes [17].
Because development of therapeutic interventions to effectively
counteract the complications of HIV PIs based therapy is
especially urgent, we have investigated whether FXR agonism
protects against dyslipidemia and vascular injury induced by
ritonavir, a widely used HIV-PIs, in rodent models of dyslipide-
mia-driven atherosclerosis.
Results
FXR Agonism Protects Against Dyslipidemia Induced By
Ritonavir
HIV-PIs are thought to influence the development of cardiovas-
cular disease primarily through increasing plasma triacylglycerols and
cholesterol levels [5–8]. Because FXR gene ablations promotes a pro-
atherogenic lipid profileand FXR ligands rescue fromdyslipidemia in
rodents, we have investigated whether FXR agonism attenuates
dyslipidemia caused by ritonavir a widely used HIV-PI in mice. The
natural FXR ligand CDCA was used because it effectively reduces
plasma triacylglycerols levels in dyslipidemic patients [21,22].
We found that 10 days administration of ritonavir to wild type
mice increased plasma triacylglycerols, FFA, cholesterol and LDL.
This effect was abrogated by co-treating wild type mice with CDCA,
and gemfibrozil, a clinically used PPARa, agonist (Figure 1; p,0.05;
n=5–6 per group). Administering mice with ritonavir had no effect
on liver weight and liver weight/liver bodyweight ratio (Figure 2A,
n=5,6; P.0.05), but increased significantly the liver content of
triacylglycerols (Figure 2B, n=5,6; P,0.05). Liver accumulation of
triacylglycerols translated in the appearance of liver steatosis as
demonstrated by the histopathology analysis shown in Figure 2C.
Indeed, staining of liver sections with H&E demonstrates that
exposureto ritonavir (5 mg/kg) resulted in a microvescicular steatosis
and hepatocyte ballooning with minor portal and lobular inflamma-
tion. Administering mice with an FXR and a PPARa agonist in
combination with ritonavir effectivelyreduced the severity of the liver
microsteatosis, (Figure 2 C). The morphometric analysis of liver
sections stained with Oil red-o, a measure of liver triacylglycerols
content, confirmed this pattern and corroborated biochemical tissue
analyses (Figure 2D). To gain mechanistic insights on the effect
exerted by ritonavir we have profiled the liver expression of genes
involved in lipid and cholesterol homeostasis and found that treating
mice with ritonavir caused a shift in the liver expression of genes
involved in lipid homeostasis including SREBP1c and FAS
(Figure 2E; n=6; P,0.05), and genes involved in cholesterol
synthesis, such as SREBP2 and HMCoA synthase, although the
later was not statistically significant. Co-treating mice with gemfibro-
zil and CDCA, attenuated this in pattern. Specifically, CDCA
effectively prevented the induction of SREBP1c and FAS caused by
ritonavir (Figure 2E, n=6; p,0.05), thought that no changes were
observed in the expression of SREBP2 and HMCoA synthase
(Figure 2E). Administering mice with CDCA also increased the
expression ofSHP mRNA, an nuclear receptor and FXRtarget gene.
Finally, both CDCA and gemfibrozil increased the liver expression of
PPARa mRNA (Figure 2E; n=6; p,0.05 versus ritonavir alone).
FXR gene Ablation Exacerbates the Dyslipidemia Caused
by Ritonavir
Because these data indicate that FXR agonism effectively
reduced the severity of dyslipidemia caused by ritonavir, we have
investigated in an independent set of experiments whether FXR
gene ablation would exacerbate the dyslipidemia caused by the
administration of this HIV-PI. As shown in Figure 3, FXR gene
ablation exacerbated the severity of dyslipidemia caused by
ritonavir (Figure 3A–F, n=6–8; P,0.05). In addition, mice
harbouring a disrupted FXR gene had a more pronounced liver
steatosis (Figure 3H) and developed a specific pattern of liver
expression of genes involved in lipid and cholesterol metabolism.
The main feature of the later being the robust dysregulation of
FAS mRNA expression and the marked reduction of the
expression of PPARa and SHP mRNAs (Figure 3I; n=6;
p,0.05).
FXR Activation Protects Against Atherosclerosis
Development In ApoE
2/2 Mice Treated With Ritonavir
Treating ApoE
2/2 mice with the HIV-PI ritonavir alone or in
combination with CDCA, and gemfibrozil for three months had
no effect on mice body weight and mortality (data not shown).
Administration of ritonavir (5 mg/kg/day) to ApoE
2/2 however,
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(Figure 4A, n=10 per group; P,0.05). The development of aortic
plaques was significantly attenuated by co-treating ApoE
2/2 mice
fed ritonavir with CDCA and gemfibrozil (P,0.05 and P,0.01
respectively; Figure 4A). Analysis of Sudan IV staining of whole
aortas, to measure neutral lipid content in the vessel, demonstrated
that ritonavir exacerbated plaque lipid accumulation in ApoE
2/2
mice and that this effect was robustly attenuated by both CDCA
and gemfibrozil (Figure 4B; P,0.01).
When compared to their wild-type counterparts, ApoE
2/2 mice
showed a twofold increase in plasma cholesterol and triglycerides
levels, a fourfold increase in plasma LDL levels and threefold
decrease in plasma HDL levels (Figure 4C–H; n=10; P,0.01).
Twelve-week administration of ritonavir failed to modify this
pattern and pharmacological treatments were also unable to
attenuate this pro-atherogenic lipid profile (Figure 4; n=10;
P,0.05 versus ritonavir). Because, the later finding was in a striking
contrast with previous observations demonstrating that FXR
agonism protects against development of pro-atherogenic lipid
profile in ApoE
2/2, we have investigated whether resistance to the
ipolipemic effectsofCDCAandgemfibrozil couldbe ascribedtothe
administration of ritonavir. For this purpose ApoE
2/2 mice were
treated with CDCA and gemfibrozil for 12 weeks without ritonavir.
Results of these experiments demonstrated that both CDCA and
gemfibrozil were effective in reducing plasma levels of triacylglycer-
ols and total cholesterol in ApoE
2/2 in the absence of ritonavir
(Figure S1), strongly supporting the view that the HIV-PI was
responsible for the inability of FXR and PPARa agonists to rescue
ApoE
2/2 mice from development dyslipidemia. Finally, ritonavir
treatment had no effect on plasma glucose (Figure 4G).
Treating ApoE
2/2 mice with ritonavir caused no changes in
the pattern of liver expression of genes involved in lipid and
cholesterol metabolism, and similarly, no changes in the
expression of these gene was detected in mice administered
CDCA and gemfibrozil (Figure 5A–G).
FXR Agonism Counter-regulates the effect of Ritonavir
on CD36 expression In vivo and in vitro
As shown in Figure 6, blood monocytes isolated from ApoE
2/2
had a significant higher expression of CD36 in comparison to wild
type naive mice (44.961.9 versus 29.662.8; n=6 P,0.05).
Treating ApoE
2/2 mice with ritonavir for 12 weeks caused a
further increase of CD36 expression on circulating monocytes
(from 44.961.9 to 58.363.3; n=6; P,0.05). However, co-
treating ApoE
2/2 mice with CDCA and gemfibrozil resulted in
a robust attenuation of CD36 expression on monocyte’s cell
surface and completely reversed the effect exerted by ritonavir
(Figure 6A; P,0.05 and P,0.01 versus ApoE
2/2 naı ¨ve and
ApoE
2/2 plus ritonavir, respectively).
Previous studies have shown that HIV-PIs disrupt cellular lipid
homeostasis by increasing the levels of SREBPs and by inducing a
SREBP-related increase in CD36 expression and lipid uptake
[9,10,11,23]. We have therefore examined whether HIV-PIs
directly modulate CD36 expression in cultured macrophages. For
this purpose RAW264.7 cells, a macrophage cell line, were directly
challenged with HIV-PIs. Results from this experiment (Figure 6B)
demonstrate that ritonavir (Figure 6B–D) and atazanavir, another
clinically used HIV-PI (Figure S2), increased the cell surface
expression of CD36 in a concentration-dependent manner
(Figure 6B, n=5; P,0.05), and that this effect was abrogated by
co-treating the RAW264.7 cells with CDCA and gemfibrozil
(Figure 6C, n=5; p,0.05). Modulation of CD36 expression by
FXR and PPARa agonism correlated with a reduced uptake ac-
LDL by cultured macrophages. Thus, CDCA and gemfibrozil
Figure 1. FXR and PPAR a ligands attenuate dyslipidemia induced by the HIV protease inhibitor ritonavir in wild type mice. C57Bl/6
mice at the age of 8 weeks were administered 5 m/kg/day ritonavir alone or in combination with the FXR agonist CDCA, 15 mg/kg/day, or the PPARa
agonist gemfibrozil, 100 mg/kg/day, for 10 days. Data shown are plasmatic level of ALT, FFA, triacylglycerols, cholesterol, HDL, LDL and glucose
measured at the end of the study period. In each panel, data are mean6 SE of 12 animal per group. *P,0.05 ritonavir versus naive; **P,0.05
treatments versus ritonavir alone.
doi:10.1371/journal.pone.0013238.g001
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(Figure 6D, n=5; P,0.05 versus ritonavir alone). In addition,
exposure of RAW264.7 cells to GW4064, a non steroidal FXR
ligand, attenuated CD36 induction caused by ritonavir and
atazanavir (P,0.05; n=4; Figure S2).
We have then examined the mechanism involved in CD36
induction caused by ritonavir. As illustrated in Figure 7A exposure
of RAW264.7 to ritonavir resulted in robust increase in the
expression of CD36 mRNAs (P,0.05, n=4). This pattern was
significantly shifted by treating the cells with CDCA. Thus
exposure of RAW 264.7 cells to the FXR ligand, but not to
gemfibrozil, attenuated induction of CD36 caused by ritonavir and
reduced the expression of SREBP1c mRNA by approximately
50%, while caused a 4–5 fold increase in SHP mRNA (Figure 7 B–
C; P,0.05, versus ritonavir). Importantly, both gemfibrozil and
CDCA increased the expression of ABCA1, a gene involved in
cholesterol secretion by macrophages (Figure 7D; P,0.05 versus
ritonavir alone).
In addition to these genomic effects, ritonavir interfered with
cell handling of SREBP1c. Thus exposure of RAW264.7 to
ritonavir leads to its translocation to the nucleus, an event that is
associated with binding of this regulatory factor to its target genes
(Figure 7E), This effect was robustly attenuated by CDCA but not
by gemfibrozil, indicating that FAXR and PPARa agonists act on
different steps of post-translation regulation of CD36.
The expression of the CD36 gene should be properly regulated
to ensure its functions [24,25]. Because an involvement of SREBPs
in the activation of CD36 is an interesting possibility of
coordination of a homeostatic balance between fatty acids and
sterols, we have examined whether SREBP1c mediates CD36
mRNA upregulation caused by HIV-PIs. For this purpose
expression of SREBP1c in RAW264.7 macrophages was knocked
down by transfecting the cells with a validated anti-SREBP1c
siRNAs. As shown in Figure 7F, transfecting the cells with anti-
SREBP1c siRNAs resulted in robust downregulation of SREBP1c
mRNA (approximately 70%, P,0.05 versus naive cells). The
Figure 2. FXR and PPAR a ligands attenuate liver steatosis induced by the HIV protease inhibitor ritonavir in wild type mice. Panel
A. Liver weight/liver bodyweight ratio after 10 days of administration of ritonavir alone or combination with CDCA or gemfibrozil. Panel B. Liver
triacylglycerols (mg/mg protein) content. Treating mice with CDCA and gemfibrozil protected against increased liver triacylglycerols accumulation
caused by ritonavir. In both panel A and B, data are mean6 SE of 12 animal per group. *P,0.05 ritonavir versus naive; **P,0.05 treatments versus
ritonavir alone. Panel C and D. Histophatologic analysis of livers obtained from wild type mice administered with ritonavir alone or in combination
with CDCA or gemfibrozil. Panel C, H&E staining, and panel D, Oil-Red-O staining, showing liver accumulation of triacylglycerols and moderate
steatosis. Treatment of mice with ritonavir (5 mg/kg) caused the appearance of microvescicular steatosis and hepatocyte ballooning with minor
portal and lobular inflammation. Administering mice with an FXR and PPARa agonist in combination with ritonavir effectively reduced the severity of
the liver microsteatosis. E&O, magnification 206; Oil red O, magnification 1006. Panel E. RT-PCR analysis of liver expression of genes involved in lipid
and cholesterol homeostasis and nuclear receptors. Treatment with ritonavir induced the expression of genes involved in triacylglycerols synthesis
(SREBP1c and FAS), as well as genes involved in cholesterol synthesis (HMCoA synthase). CDCA effectively reduced SREBP1c and FAS accumulation
caused by ritonavir while no changes are were observed in the expression of SREBP2 and HMCoA synthase. Administering mice with CDCA also
increased the expression of SHP mRNA. Finally, both CDCA and gemfibrozil increased the liver expression of PPARa mRNA. In each panel, data are
mean6 SE of 6 animal per group. *P,0.05 ritonavir versus naive; **P,0.05 treatments versus ritonavir alone.
doi:10.1371/journal.pone.0013238.g002
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CD36 (Figure 7H versus 7G) highlighting a putative role of
SREBP1c in mediating the effect of ritonavir on CD36. To gain
further insights on the mechanisms involved in the regulation of
CD36 by SREBP1c, we have carried out an analysis of the CD36
promoter in the search for a putative binding site for SREBP1c.
Because this analysis revealed the presence of a putative sterol
regulatory element (SRE)-binding consensus in the promoter of
CD36, we have performed a ChIP assay and PCR amplification
using primer pairs that cover the putative CD36-SRE consensus
site located at 276 in the CD36 promoter. Results from these
experiments, however, were negative, indicating that in
RAW264.7 cells induction of CD36 expression caused by ritonavir
is not mediated by a direct binding of SREBP1c to the CD36
promoter and is likely mediated by activation of additional
mechanisms (Figure S3).
Discussion
FXR is a nuclear receptor that functions as a bile acid sensor and
plays a regulatory role in bile acids, cholesterol and lipid
homeostasis [26]. Previous studies have shown that FXR might
be an interesting target for preventing development of atheroscle-
rosis. This contention results from the aggregate evaluation of the
factthatFXRgeneablationresultsinapro-atherogeniclipoproteins
profile [15] and FXR and ApoE double knockout male mice fed an
high fatdiet develop an accelerated atherosclerosis in comparison to
ApoE
2/2 single knock out mice [27]. In addition, we and others
have demonstrated that FXR activation protects against athero-
sclerosisplaqueformationinApoE
2/2 and LDLr
2/2 mice [16,17].
In the present study we have provided evidence that FXR
activation with CDCA effectively protects against dyslipidemia
and atherosclerosis development in rodents fed ritonavir, a widely
used HIV PI (Figure 8). Despite the fact that synthetic and semi-
synthetic FXR ligands are currently investigated [26], we have
decided to use CDCA, the natural FXR ligand, for the following
reasons. The prevalence of HIV infection is growing in
undeveloped countries [1–3] and the cost of co-medications to
prevent HAART’s related side effects add significantly to the
already elevated cost for HAART itself. Our aim was therefore to
exploit a drug that would have beneficial effects without increasing
further the costs of HIV management. CDCA has a low cost and is
the only FXR ligand available worldwide that has been
Figure 3. FXR gene ablation worsens the severity of dyslipidemia caused by ritonavir. Panel A–F. Plasmatic level of ALT, triacylglycerols,
cholesterol, HDL, LDL and glucose in wild type and FXR
2/2 mice administered ritonavir, 5 mg/kg/day, for 10 days. In each panel, data are mean6 SE
of 6 animal per group. *P,0.05 versus wild type naive; **P,0.05 treatments versus ritonavir wild type. Panel G. Liver weight/liver body weight ratio
after 10 days administration of ritonavir. In each panel, data are mean6 SE of 8 animal per group. Panel H. Liver histophatology. H&E staining of liver
sections obtained from FXR
+/+ and in FXR
2/2 mice. Magnification 206. Figure I. RT-PCR analysis of liver expression of genes involved in lipid and
cholesterol homeostasis and nuclear receptors. Treatment with ritonavir caused a significant dysregulation of FAS mRNA expression in FXR
+/+ and
FXR
2/2 mice. FXR
2/2 mice show a severe reduction of liver expression of SHP and PPARa mRNA that is insensitive to ritonavir. In each panel, data are
mean6 SE of 6 animal per group. *P,0.05 versus wild type naive; **P,0.05 treatments versus ritonavir wild type.
doi:10.1371/journal.pone.0013238.g003
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[21,22].
FXR activation protects against development of
dyslipidemia in wild type mice
HAART has had a dramatic effect in reducing morbidity and
mortality associated with HIV-1 infection. However, concern has
been raised in relation to the increased risk of coronary heart
disease linked to chronic use of HAART. Findings from the Data
Collection on Adverse Events of Anti-HIV Drugs (DAD) study
indicate that the incidence of myocardial infarction in HIV
infected persons increases with long-term exposure to HAART
[2–4,8]. In a large prospective observational study including
23,437 patients the incidence of myocardial infarction increased
from 1.53 per 1000 person-years in those not exposed to HIV PIs
to 6.01 per 1000 person-years in those exposed to HIV PIs for
more than 6 years. After adjustment for exposure to the other drug
class and established cardiovascular risk factors (excluding lipid
levels), the relative rate of myocardial infarction per year of HIV
PIs exposure was 1.16 (95% confidence interval [CI], 1.10 to
1.23). Despite adjustment for serum lipid levels further reduced the
effect of exposure to each drug class to 1.10 (95% CI, 1.04 to 1.18),
these results demonstrate that exposure to protease inhibitors is
associated with an increased risk of myocardial infarction which is
only partly explained by dyslipidemia. In contrast, there is no
evidence that the use of non-nucleoside reverse-transcriptase
Figure 4. FXR and PPAR a ligands protects against aortic plaques formation induced by the HIV-PI ritonavir to ApoE
2/2 mice. Panel
A. Administration of ritonavir (5 mg/kg/day) to ApoE
2/2 for 12 weeks increases the size of aortic plaques expressed of ratio of plaque surface area to
vessel surface area. The effect was significantly attenuated by co-treating mice with gemfibrozil or CDCA. Individual data of 10 animals per group are
shown. *P,0.05 versus wild type naive; #P,0.05 treatments versus ritonavir. Panel B. Pseudo-colour representation of aortic plaques from
individual animals. The images show the plaque surface from individual animals, each one representative of a specific experimental group. The lipids
in the vessel wall were staining with Sudan IV, as described in Material and Methods, and shown in red. Panel C–H. Plasmatic levels of ALT,
triacylglycerols, cholesterol, HDL, LDL and glucose in ApoE
2/2 mice. ApoE
2/2 mice show increased plasma cholesterol, triacylglycerols and LDL
plasma levels and decreased HDL plasma levels in comparison to their wild-type counterparts (n=10; * P,0.01 versus naive wild type). Twelve-weeks
administration of ritonavir failed to change this pattern and pharmacological treatments were unable to attenuate the pro-atherogenetic lipid profile
observed in ApoE
2/2 administered ritonavir (n=10).
doi:10.1371/journal.pone.0013238.g004
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infarction [28,29].
Beside the DAD study, smaller studies have provided evidence
that long-term use of HAART regimens based on HIV PI
lopinavir/ritonavir increases the levels of triglycerides and results
in a pro-atherosclerotic lipoprotein profile [5–7]. These studies
indicate that the hyperlipidemia produced by HIV PI is primarily
attributable to an excessive FFA mobilization occurring because of
insulin resistance in the adipose tissue, resulting in increased
VLDL–triglyceride production and apoB synthesis. Likewise, t in
fed mice, ritonavir had no effect on serum glucose and cholesterol,
whereas triglyceride and fatty acids increased by 57% to 108%
[30]. In fasted mice, ritonavir increased serum glucose by 29%,
cholesterol by 40%, and triglyceride by 99%. The hyperlipidemia
was attributed to elevated FFA and cholesterol synthesis by the
liver and adipose tissue caused by activation of SREBP1c and 2,
whereas studies in cultured liver cells support the notion that
ritonavir might cause a decreased degradation of nascent apoB
attributable to inhibition of the 20S proteasome.
In the present study we have confirmed that administration of
ritonavir to wild type mice increases triacylglycerols synthesis. A
two-fold increase in FFA, triacylglycerols and LDL plasma levels
was observed in mice administered 5 mg/kg/day ritonavir for 10
days, indicating that this model reproduces all major metabolic
features observed in HIV infected persons administered liponavir/
ritonavir. A major observation of the present study was the
demonstration that such lipid abnormalities are highly dependent
on the activity of the nuclear receptor FXR. Thus, not only
activation of FXR with CDCA protects against development of
dyslipidemia caused by ritonavir, but feeding ritonavir to FXR
2/2
mice resulted in an exacerbation of biochemical derangements
caused by the HIV PI in wild type mice. Together, these
observations provide a strong support to the notion that FXR
might be a novel therapeutic target for preventing/treating lipid
metabolism abnormalities caused by HIV PI.
Feedingwith FXR agonistsattenuatesdyslipidemiain a varietyof
rodent models [16–20]. A key regulatory pathway involved in these
effects is the inhibition of SREBP1c. Administering rodents with
natural and synthetic FXR ligands inhibits the expression of
SREBP1c in the liver. Originally, this effect was thought to be
mediated by SHP, an atypical nuclear receptor that lacks a DNA
binding domain. Based on studies in SHP-deficient mice, it has been
proposed that the induction of SHP mediates the downregulation of
SREBP-1cexpressioninresponsetobile acidstreatment[18,19,31].
Counter-intuitively, however, a decreased, and not increased,
SREBP-1c mRNA is observed in ob/ob/SHP
2/2 double mutants
[32]. In addition to the observation that transgenic mice
constitutively expressing SHP in the liver exhibited an enhanced
expression of SREBP-1c mRNA levels and a concomitant
accumulation of hepatic triglycerides [33], these data suggest that
alsoa SHP-independent mechanism is activated by FXR ligands. In
the present study we have shown that CDCA induced the liver
expression of SHP and was as effective as the PPARa ligand
gemfibrozil in correcting lipid abnormalities caused by ritonavir.
Figure 5. FXR and PPARa ligands does not impact on liver expression of genes involved in lipid and cholesterol metabolism in
ApoE
2/2 mice administered the HIV-PI ritonavir. In each panel, data are mean6 SE of 6 animal per group. *P,0.05 versus wild type naı ¨ve mice.
doi:10.1371/journal.pone.0013238.g005
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LDL-lowering effect. Both agents had minor effect on cholesterol
plasma levels, confirming that ritonavir increases LDL levels
primarily by inducing FFA and triacylglycerols synthesis.
A further confirmation of this view comes from results of
experiments carried out in FXR
2/2 mice. Indeed, challenging
FXR
2/2 mice with ritonavir exacerbated the severity of
dyslipidemia induced by ritonavir causing a two-fold increase in
FFA, triacylglycerols and LDL plasma levels in comparison to wild
type mice administered the HIP-PI. Administering FXR
2/2 mice
with ritonavir also increased cholesterol and reduced HDL levels.
The latter effect is commonly observed in response to FXR
activation, and it is still unclear whether it holds any potential for
detrimental side effects in humans.
Analysis of the expression of regulatory genes in the liver
revealed that ritonavir had a minor effects on expression of
SREBP1. However, expression of this gene was reduced in mice
administered CDCA. Our results are consistent with previous
observations indicating that ritonavir increases SREBP1c by
reducing its degradation and by causing its stabilization at the
promoter of target genes [9,10]. In summary these results suggest
that activation of FXR reverts lipid abnormalities caused by
ritonavir and that FXR gene ablation exacerbates the dyslipidemia
caused by this HIV PI.
FXR activation protects against atherosclerosis
development in ApoE
2/2 mice fed ritonavir
An important observation we made is that, in contrast to wild
type mice, 12-weeks administration of ritonavir (5 mg/kg/day) to
ApoE
2/2 mice failed to exacerbate the dyslipidemic phenotype
of these mice and that, while pharmacological treatments were
effective in protecting against accelerated atherosclerosis, both
the FXR and PPARa ligand had no effect on serum lipoprotein
profile. The lack of the effect on lipid metabolism was confirmed
by the analysis of the expression of regulatory genes in the liver.
Thus, in striking contrast to what observed in wild type mice,
both CDCA and gemfibrozil failed to modulate the liver
expression of SREBP1c, SREBP2and FAS. In addition, both
treatments had no effects on liver expression of PPARa and
FXR. Thought that CDCA increased the liver expression of
SHP.
In a previous study we have demonstrated that activation of
FXR, by a semi-synthetic derivative of CDCA and PPARc
reduces the liver expression of SREBP1c and its target genes
Figure 6. FXR and PPAR a ligands revert the dsysregulation of CD36 expression caused by administration of the HIV-PI ritonavir to
ApoE
2/2 mice. Panel A. CD36 expression on circulating was induced by administering ApoE2/2 mice with ritonavir 5 mg/kg/day for 12 week
(n=6 P,0.05) s. Co-treatment with gemfibrozil or CDCA abrobated this effect. Data are mean6 SE of 12 animal per group. *P,0.05 versus wild type
naive; **P,0.05 versus ApoE
2/2; # P,0.05 treatments versus ritonavir alone. Panel B–E. Ritonavir, gemfibrozil and CDCA exert opposite
effects on CD36 expression/function in cultured macrophages (RAW264.7 cells). Ritonavir treatment increased the cell surface expression
of CD36 on cultured macrophages in a concentration-dependent manner (Figure 6B, n=5; P,0.05) and co-treatment of the cells with gemfibrozil
and CDCA (Figure 6 C,D n=5; p,0.05) reduced CD36 expression caused by 10 mM ritonavir by approximately 75% (Figure C,D; n=5; P,0.05).
Exposure of RAW264.7 cells to 10 mM ritonavir increased CD36-mediated uptake of acetylated LDL (ac-LDL). This effect was abrogated by gemfibrozil,
250 mM, and CDCA, 50 mM (n=5; P,0.05 versus ritonavir alone).
doi:10.1371/journal.pone.0013238.g006
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2/2 mice, administered a non-fat diet [17].
In the present study we have confirmed that CDCA similarly to its
derivative 6-ethyl CDCA, protects against development of a
dyslipidemic phenotype in ApoE
2/2 mice not administered
ritonavir (Figure S1), strongly indicating that feeding ApoE
2/2
mice with an HIV PI introduces a further distortion of the
metabolic regulation that can not be reverted by FXR and PPARa
ligand in this model.
The fact that CDCA protects against atherosclerotic plaque
formation in ApoE
2/2 despite it had no effect on lipid profile,
indicates that FXR activation might impact on expression on pro-
inflammatory factors [34–40]. Thus, in vivo and in vitro studies,
have demonstrated that HIV PIs increase atherosclerotic lesions
by a direct action on macrophages [12]. Macrophages play an
essential role in atherosclerosis [41]. Gene-deletion and bone
marrow–transplantation experiments have provided evidence that
macrophages scavenger receptor A and CD36 exert non
dispensable effects in mediating the uptake of oxidized LDL by
macrophages and promoting the development of atherosclerosis
[42,43]. CD36 is the primary mediator of cholesterol accumula-
tion in atherosclerosis induced by HIV PIs [12]. One important
observation we made is that while administration of ritonavir to
ApoE
2/2 mice increased the percentage of CD36 positive
monocytes, chronic administration of CDCA caused a robust
reduction in the percentage of CD14/CD36 positive cells in
ApoE
2/2 mice treated with ritonavir. A similar pattern was
observed when CD36 mRNA expression was measured in the
aortic plaques. Similarly to CDCA, gemfibrozil was also effective
in attenuating CD36 expression in the aorta and circulating
macrophages. These data are consistent with our previous
observations indicating that activation of FXR attenuates the
expression/function of CD36 in ApoE
2/2 naive mice.
The above results were confirmed by in vitro studies. Thus,
while treating RAW264.7 macrophages with ritonavir and
atazanivar resulted in a concentration-dependent induction of
CD36 expression, gene and protein, this effect was completely
abrogated by treating the cells with CDCA and GW4064 (a
synthetic FXR agonist). The concentration of ritonavir used in this
experiment is clinically relevant. Indeed, while plasma concentra-
tions of ritonavir in HIV infected patients treated with ritonavir
Figure 7. Distinct patterns of gene and protein expression are induced by FXR and PPARa ligands in macrophages challenged with
ritonavir. Panel A–D. RT-PCR analysis of gene expression induced by exposure RAW264.7 cells to ritonavir alone or in combination with a PPARa or
FXR ligand. Ritonavir slightly increased expression of CD36 mRNA (Figure 7A) while CDCA, but not gemfibrozil, completely abrogated this effect. In
addition exposure CDCA, but not to gemfibrozil, reduced SREBP1c mRNA and increased the expression of SHP mRNA (P,0.05 versus ritonavir). In
each panel, data are mean6 SE of 5 separate experiments. Panel E. Detection of nuclear translocation of SREBP1c by Western blot analysis.
Treatment of RAW264.7 cells with ritonavir increased protein level of SREBP1c and caused its nuclear translocation. Activation of FXR with CDCA
reduced total SREBP1c protein and prevented its nuclear translocation. Data shown is representative of three other experiments showing the same
pattern. Panel F–H. Transfection of RAW264.7 macrophages with an anti-SREBP1c siRNAs resulted in a robust downregulation of SREBP1c mRNA
(<70%, P,0.05 versus naive cells). The knock-down of SREBP1c abrogated the ability of ritonavir to induce CD36 (panel 7H versus panel G). In each
panel, data are mean6 SE of 4 separate experiments.
doi:10.1371/journal.pone.0013238.g007
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peripheral blood mononuclear cells reaching concentrations of
<20 mM. Importantly, while CDCA and GW4064 had no effect
on basal expression of CD36 both agents were effective in
reducing CD36 protein expression induced by 10 mM of ritonavir
as measured by flow cytometry. Further on, modulation of CD36
expression was functionally correlated with a reduction of ac-LDL
uptake by macrophages.
Several of our results indicate that FXR directly antagonizes the
effect of ritonavir on CD36 by interacting with SREBP1c. Exposure
to ritonavir induces the expression of SREBP1c mRNA as well as its
nuclear accumulation. Our results are therefore a variation of
previous studies reporting that ritonavir inhibits SREBP1c degrada-
tion [9]. The genomic effects of ritonavir could be explained by
several mechanisms. In macrophages, HIV PIs activate the unfolded
protein response (UPR) which is involved in the regulation of CD36
expression an event that has been involved in foam cell formation
[11]. Despite FXR ligands have no effect on post-translational
handling of SREBP1c we have found that FXR ligation reduces total
SREBP-1c, protein and mRNA levels, by approximately 50%
therefore reducing its nuclear translocation. In the present study we
h a v ef o u n dt h a tC D C Ac a u s e sa4 – 5f o l di n c r e a s eo fS H Pm R N A
and we have documented an inverse correlation between SHP and
SREBP-1 expression in RAW264.7 cells exposed to CDCA. These
data are consistent with the finding that FXR activation by natural
and synthetic agonists represses the expression of SREBP-1c and
its lipogenic target genes in mouse primary hepatocytes and in liver
[18–20,33]. One important observation we made is that exposure of
EAW264.7 cells to CDCA resulted in robust induction in the
expression of ABAC1, a gene whose protein product mediates
cholesterol efflux from macrophages. The ability of FXR to induce
ABCA 1 expression could be of mechanistic relevance in explaining
the anti-atherogenic effects of CDCA [44].
Several experimental data link SREBP responsive elements
(SRE) to the regulation of CD36 gene expression. Thus, knocking
down the expression of SREBP1c greatly attenuated the induction
of CD36 caused by ritonavir. However, despite we have identified
a putative SRE-binding site in the promoter of mouse CD36 gene,
we have been unable to show a functional role for this SRE in
RAW264.7 cells exposed to ritonavir, indicating that ritonavir
induces CD36 expression by multiple, yet not completely
identified, pathways.
Despite the present study demonstrates that FXR activation
attenuates dyslipidemia caused by ritonavir, this is a preclinical
Figure 8. Diagramatic representation of the effect exerted by FXR and PPARa ligands on dyslipidemia and accelerated
atherosclerosis caused by the HIV-PI ritonavir. Exposure to ritonavir causes SREBP1c activation in the liver and monocytes. In circulating
monocytes ritonavir causes a SREBP1c-dependent induction of CD36. Increased expression of CD36 leads to uptake of ac-LDL and favours the
acquisition of an activated phenotype by monocytes and their transformation into foam cells. Activation of FXR, reduces CD36 expression on
macrophages by interfering with SREBP1c. Knocking down SREBP1c by siRNAs abrogates the activation of CD36 caused by ritonavir. Activatory
pathways are shown in black and inhibitory pathways in red.
doi:10.1371/journal.pone.0013238.g008
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some cautions. Indeed, the causes of dyslipidemia in HIV infected
patients taking a PI are not completely clarified.
In addition to the above described mechanisms, alternative
regulatory pathways could have been activated by exposure of
macrophages to ritonavir. The pregnane –x-receptor (PXR) is a
nuclear receptor and xenobiotic sensor and is a ritonavir target
gene. Previous studies have shown that PXR directly activates
SREBP1c and CD36 by binding to PXR responsive elements in
the CD36 promoter. However, we have ruled out a possible role
for PXR in the negative regulatory effects exerted by FXR
agonists on this scavenger receptor, because FXR is a known PXR
inducer [45,46]. Thus, exposure to FXR ligand would results in
the induction of PXR, that is a positive regulatory gene for CD36.
In conclusion, we have provided evidence that FXR activation
exerts anti-atherosclerotic effects in ApoE
2/2 mice treated with an
HIV PI and that these effects are independent on modulation of
lipid metabolism, but requires the regulation of CD36 expression
and activity. These data suggest that CDCA by modulating
SREPBP1c expression specifically antagonizes the effects of
ritonavir of CD36, a mechanism involved in dyslipidemia caused
by HIV-PI.
Materials and Methods
Animal and treatments
The present study involves the use of rodents. All experiments
were performed in accordance to international and Italian
guidelines for use of laboratory animals. The present protocol
was approved by the Italian Minister Health and conforms to
national guidelines. The ID for this project is #11/2010-B. The
authorization was released to prof. Stefano Fiorucci, as a principal
investigator, on January 25, 2010. Mice were maintained in a
temperature controlled facility with a 12-hour light/dark cycle and
were given free access to food and water. Eight weeks old wild type
and FXR
2/2 mice were randomized into four groups (N=10):
group 1, no treatment; group 2 intraperitoneally administration of
ritonavir 5 mg/Kg/day in a total volume of 100 ml alone; groups 3
and 4 received ritonavir (5 mg/Kg/day) in combination with
CDCA (20 mg/kg/day by gavage) and gemfibrozil (100 mg/kg/
day by gavage) respectively. While FXR null mice, eight weeks old,
were randomized into two groups (N=10): group 1, no treatment
and group 2 intraperitoneally administration of 100 ml ritonavir
(5 mg/Kg/day) alone. All drugs were administered 14 days.
During the experiment mice were weight once a week. At the end
of the experiment, 12-hour fasted animals received the latest
administration of the specific agent and 6 hours later were
anesthetized with sodium pentobarbital and then sacrificed. Blood
and livers were collected. Serum content of total cholesterol,
triglyceride, HDL, LDL, glucose and alanine aminotransferase
were measured by enzymatic assays (Wako Chemicals; Osaka,
Japan).
ApoE
2/2 male mice on a C57BL6/J background and wild type
C57BL6/J male mice were from the Harlan Nossan (Udine, Italy).
Ten weeks old ApoE
2/2 mice were randomized into four groups
(n=10 per group): group 1, no treatment; group 2 mice were
administered intraperitoneally with 100 ml of a solution containing
5 mg/Kg/day ritonavir; groups 3 and 4 mice were administered
with r ritonavir (5 mg/Kg/day) in combination with CDCA
(15 mg/kg/day by gavage) or gemfibrozil (100 mg/kg/day by
gavage) respectively. All drugs were administered five days a week
for 12 weeks. During the experiment mice were weight once a
week. At the end of the experiment animals were fasted for
16 hours, anesthetized with sodium pentobarbital before harvest-
ing blood for subsequent lipid measurements and monocytes/
macrophages isolated for the measurement of CD36 expression by
flow cytometry. Liver samples for RNA isolation were immediately
snap frozen. Liver samples for histology were embedded in
paraffin. The aortas were processed for enface atherosclerotic
lesion coloration. This protocol was repeated three fold and results
on one experiment are shown. In the second set of experiments (8
mice per group), animals received the same treatments described
above and at the end blood was collected for RNA isolation and
monocytes/macrophages isolated for CD36 expression.
Quantification of atherosclerotic plaques and liver
histology
The heart and upper section of the aorta were removed from
animals, cleaned of peripheral fat under a dissecting microscope,
and sectioned parallel to the atria leaflets. En face analysis, aortas,
including the ascending arch, thoracic, and abdominal segments,
were dissected, gently cleaned of the adventitia, and stained with
Sudan IV. Exactly the aortic parts were then stretched between
two glass plates and fixed in neutral aqueous phosphate-buffered
formaldehyde solution. The fixed aortic parts were stained en face
with a filtrated solution containing Sudan IV (0.5 g Sudan IV
dissolved in 200 ml ethanol:acetone:H2O, 21:10:9, vol/vol/vol;
Sigma Chemical, Milan, Italy) to demonstrate areas of developed
atheromatous plaques. To identify early atherosclerotic lesions, the
aortas were then stained with Sudan IV without removing the
pins. Aortas were briefly rinsed in 70% ethanol, immersed for
6 minutes in a filtered solution containing 0–5% Sudan IV (Sigma
Chemical Co), 35% ethanol, and 50% acetone for 6 minutes, and
destained for 5 minutes in 80% ethanol. The mean lesion area was
quantified from ten digitally captured sections per mice using a
BX60 microscope (Olympus Co., Rome, Italy) and digitalized
using a SPOT-2 camera (Diagnostic Instruments Inc., Sterling
Heights, MI) with a resolution of 131561033 pixels. Area
measurements (expressed in pixels) were done using the free
software Image J 1.33u (Rasband W., National Institutes of
Health; Bethesda, MD). For liver histology, samples of the right
and left liver lobes (100 mg/each) taken from each animal were
fixed in 10% formalin, embedded in paraffin, sectioned, and
stained with H&E.
Tissue triacylglycerols and FFA
For determination of total triglyceride, cholesterol and FFA
(N=6-4) content about 100 mg fragments of liver or heart were
homogenized with 1 ml of T-PER (Pirce). The homogenized were
used for protein concentration, Bradford assay (Bio-rad), and at
100ml of lised tissue extract was added 1.6 ml CHCl3 : MeOH
(2:1) for 16 h at 4uC, after which 200mL of 0.6% NaCl was added
and the solution centrifuged at 2,000 g for 20 min. The organic
layer was removed and dried by speed vac system (HETO-
Holten). The resulting pellet was dissolved in 100mL of phosphate
buffered saline containing 1% Triton X-100 and triglyceride and
free fatty acids content ware determined using specific enzymatic
reagents, the results were expressed for mg of protein.
Flow cytometry quantification of CD36 expression on
monocytes/macrophages
Blood-derived macrophages were collected from wild-type and
ApoE2/2 mice (n=12/genotype) as described in the previous
section. The cells were treated with ACK solution to eliminate red
blood cells, stained by anti-CD14-PE antibody and anti-CD36
antibody (BD Biosciences Pharmingen, San Diego, USA) and
analyzed by a flow cytometer (Beckman Coulter, Fullerton, CA).
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RAW264.7 cells were obtained from ATCC (Manassas, USA),
cultured in RPMI 1640 medium (Sigma) supplemented with 10%
fetal bovine serum (Gibco BRL), 100 U penicillin per milliliter,
100 mg of streptomycin per milliliter, and incubated in 10% CO2
in air at 37 8C. Cells were plated on six-well plates (100.000 for
well). The medium was replaced after 24 h, and treated. Ritonavir
and Atazanavir were dissolved in DMSO. In the first set of
experiments HIV PI were directly added to culture medium (final
concentration, 5 to 40 mM, DMSO 0.1%) alone for 16 hours at
the end of incubation the cells were collected to evaluated cells
dead and CD36 expression by flow cytometry. In a second set of
experiments the cells were preincubated for 24 h with Genfibrozil
(250mM) or CDCA (50mM) and then treated with ritonavir 10 mM
for 16 h, at the end of incubation the cells were collected to
evaluated CD36 expression by flow cytometry and for mRNA
extraction. Total RNA (10 mg) was used for first-strand cDNA
synthesis. The mRNA levels of, CD36, SREBP1-2, SHP and
PPARc were determinate by quantitative real-time polymerase
chain reaction (qRT-PCR).
Measurement of Cholesterol up-take
Mouse RAW264.7 macrophages were plated on six-well plates
(100.000 for well). The medium was replaced after 24 h, and cells
were preincubated for 24 h with Genfibrozil (250mM) or CDCA
(50mM) and then treated with ritonavir 10 mM for 16 h, at the end
of incubation 10mg/ml of low density lipoprotein acetylated Dil
complex (Dil AcLDL) (Molecular Probe, Oregon, USA) was added
for 3 hours at 37u. At the end of incubation, cells were collected
and washed with PBS and the LDL up-take were measured by
flow cytometer (Beckman Coulter, Fullerton, CA).
Real-time PCR analysis
Quantification of genes expression in tissues was performed by
qRT-PCR as described previously [44]. Quantization of the
expression of selected genes was performed by quantitative real-
time PCR (qRT-PCR). Total RNA were obtained from livers and
cells and isolated with TRIzol reagent (Invitrogen), incubated with
DNase I and reverse-transcribed with Superscript II (Invitrogen)
according to manufacturer specifications. For real-time PCR,
100 ng of template was used in a 25-ml reaction containing a
0.3 mM concentration of each primer and 12.5 mlo f2 6 SYBR
Green PCR Master Mix (Bio-Rad Laboratories, Hercules, CA).
All reactions were performed in triplicate using the following
cycling conditions: 2 min at 95uC, followed by 50 cycles of 95uC
for 10 s and 60uC for 30 s using an iCycler iQ instrument (Bio-
Rad Laboratories). The mean value of the replicates for each
sample was calculated and expressed as cycle threshold (CT). The
amount of gene expression was then calculated as the difference
(DCT) between the CT value of the sample for the target gene and
the mean CT value of that sample for the endogenous control
(GAPDH). Relative expression was calculated as the difference
(DDCT) between the DCT values of the test and control samples for
each target gene. The relative level of expression was measured as
2
2DDCT. All PCR primers were designed using the software
PRIMER3-OUTPUT using published sequence data obtained
from the NCBI database. Mouse primers were as follows:
mSREBP1c: gatcaaagaggagccagtgc and tagatggtggctgctgagtg;
mSREBP2: acagatgccaagatgcacaa and ttcagcaccatgttctcctg;
mFAS: tgggttctagccagcagagt and accaccagagaccgttatgc;
mHMGCoAS: ggtggatgggaagctgtcta and acatcatcgagggtgaaagg;
mHMGCoAR: ccgaattgtatgtggcactg and ggtgcacgttccttgaagat;
PPARc: gccagtttcgatccgtagaa and aatccttggccctctgagat;
mFXR: tgtgagggctgcaaaggttt and acatccccatctctctgcac;
mSHP: tctcttcttccgccctatca and aagggcttgctggacagtta;
mCD36: cggagacatgcttattgagaa and actctgtatgtgtaaggacct
mABCA1: agccagaagggagtgtcaga and catgccatctcggtaaacct;
mGAPDH: ctgagtatgtcgtggagtctac and gttggtggtgcaggatgcattg;
m18S: accgcagctaggaataatgga and gcctcagttccgaaaacc.
Nuclear and cytoplasmic extracts
Nuclear and cytoplasmic extracts from Raw264.7 cells left
untreated or administered with 10 mM Ritonavir alone or in
combination with 50 mM CDCA or with 250 mM Gemfibrozil
were made with the NE-PER kit (Pierce) according to the
manufacturer’s protocol.
Western Blotting. Total lysates from RAW264.7 cells were
prepared by solubilization in NuPAGE sample buffer containing
Sample reducing agent. Proteins were separated by polyacrylamide
gel electrophoresis, transferred to nitrocellulose membranes (Bio-Rad,
Hercules, CA) and than probed with primary anti-SREBP-1 antibody
(Santa Cruz Biotech, Santa Cruz, CA). The anti-immunoglobulin G
Rabbit (Bio-Rad) was used as a secondary antibody, and specific
protein bands were visualized by chemoluminescence using Super
Signal West FEMTO reagent (Pierce, Rockford, IL).
Electrophoretic mobility shift assay (EMSA)
Preparation of nuclear extract from RAW264.7 cells was done
usingNE-PER(Pierce).TheprobesusedforEMSA(CD36-SREwild
type and mutated) were labelled with biotin using Biotin 39 end DNA
labelling kit (Pierce) according to the manufacturer’s instructions. For
EMSA,5 mg of nuclear extract from RAW264.7 cellsnaive or treated
with ritonavir alone or in combination with Gemfibrozil or CDCA
were incubated with 15 fmol of the CD36-SRE probe, while 5 mgo f
nuclear extract from stimulated cells was incubated with CD36-SRE-
mutated probe in a total volume of 20 mL of binding buffer
(50 mmol/L NaCl, 10 mmol/L Tris-HCl, pH 7.9, 0.5 mmol/L
EDTA, 10% glycerol, 1 mg of poly dI-dC) for 20 min at room
temperature. For competition assays, an excess of CD36-SRE
unlabeled oligonucleotides were pre-incubated with nuclear
extract from treated cells for 15 min prior to the addition of the
biotin-labelled CD36-SRE probe. For antibody-mediated super-
shift assay, extracts from stimulated cells were pre-incubated with
1 mg anti-SREBP-1 antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) at room temperature for 20 min before the
addition of the biotin-labelled CD36-SRE probe. The reactions
were loaded on a 6% polyacrylamide non-denaturing gel in 0.56
Tris-borate-EDTA buffer and electrophoresed for 1 h at 100 V.
The protein/DNA complexes were then transferred to positively
charged nylon membrane (Pierce) and the supershift was detected
using the Chemiluminescent Nucleic Acid Detection Module
(Pierce).
Additional methods aredescribed in ‘‘Materialsand MethodsS1’’.
Supporting Information
Materials and Methods S1
Found at: doi:10.1371/journal.pone.0013238.s001 (0.03 MB
DOC)
Figure S1 In the absence of ritonavir, administering ApoE
2/2
mice with an FXR and PPARa agonist reverts dyslipidemia.
Gemfibrozil and CDCA reduced plasma levels of total cholesterol,
LDL, and triacylglycerols in ApoE
2/2 mice. In each panel, data
are mean6 SE of 12 animal per group. *P,0.05 ApoE
2/2 versus
naive; # P,0.05 treatments versus ApoE
2/2.
Found at: doi:10.1371/journal.pone.0013238.s002 (0.31 MB
TIF)
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cultured macrophages RAW264.7 cells. Ritonavir and atazanavir,
two HIV PIs increases the cell surface expression of CD36 in a
concentration-dependent manner. Data are mean 6 SE of 4
separate experiments. Natural and synthetic FXR ligands, CDCA
and GW4064, counteracts CD36 induction caused by ritonavir
and atazanavir. Data are mean6 SE of 4 separate experiments.
Found at: doi:10.1371/journal.pone.0013238.s003 (0.18 MB TIF)
Figure S3 Nubiscan analysis (http://www.nubiscan.unibas.ch)
of the mouse CD36 promoter region revealed one potential
SREBP1 binding site, TTCACACCAG, located at 21562 bp
from the transcriptional starting site ATG. To assess the
functionality of this SRE (Sterol Regulatory Element) we carried
a ChIP experiment with an anti SREBP1 antibody (see Materials
and Methods S1). As shown, quantitative Real-Time PCR analysis
of the CD36 5’flanking region revealed that SREBP1 was unable
to bind to the promoter region containing the putative SRE in cells
untreated as well as in cells stimulated with ritonavir alone or with
the combination ritonavir plus CDCA. These results suggest that
SREBP1 regulates CD36 expression with an indirect mechanism.
Found at: doi:10.1371/journal.pone.0013238.s004 (0.61 MB TIF)
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